Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein

Acta Virologica

Volumn 55, Issue 1, 2011, Pages 61-67

  Stanekova Z ^a   Kiraly J ^a   Stropkovska A ^a   Mikuskova T ^a   Mucha, V ^a   Kostolansky F ^a   Vareckova E ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Cross protection; Fusion peptide of hemagglutinin; Immunogenicity; Influenza A virus; M2 protein

Indexed keywords

HYBRID PROTEIN; PROTEIN M2; VIRUS HEMAGGLUTININ; HEMAGGLUTININ HA 2 FUSOGENIC PEPTIDE, INFLUENZA VIRUS; HEMAGGLUTININ HA-2 FUSOGENIC PEPTIDE, INFLUENZA VIRUS; HEMOCYANIN; INFLUENZA VACCINE; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; PEPTIDE FRAGMENT; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DRUG CONJUGATION; DRUG SYNTHESIS; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LD 50; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COMPARATIVE STUDY; FEMALE; IMMUNOLOGY; MOLECULAR GENETICS; ORTHOMYXOVIRUS INFECTION; SURVIVAL RATE;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; FEMALE; HEMAGGLUTININS, VIRAL; HEMOCYANIN; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDE FRAGMENTS; SURVIVAL RATE; VIRAL FUSION PROTEINS; VIRAL MATRIX PROTEINS;

EID: 79957449934     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2011_01_61     Document Type: Article

References (29)

1. Cross KJ, Langley WA, Russell RJ, Skehel JJ, Steinhauer DA (2009): Composition and function of the influenza fusion peptide. Protein Pept. Lett. 16, 766-778.
2. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X (2008a): An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J. Biol. Chem. 283, 11382-11387.
3. De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londoño-Arcila P, Fiers W, Saelens X (2008b): Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 26, 6503-6507.
4. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW (2004): Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22, 2993-3003.
5. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X (2009): M2e-based universal influenza A vaccine. Vaccine 27, 6280-6283.
6. Fislová T, Gocník M, Sládková T, Ďurmanová V, Rajčáni J, Varečková E, Mucha V, Kostolanský F (2009): Multiorgan distribution of human influenza A virus strains observed in a mouse model. Arch. Virol. 154, 409-419.
7. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ (2009): Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325, 197-201.
8. Gerhard W, Mozdzanowska K, Zharikova D (2006): Prospects for universal influenza virus vaccine. Emerg. Infect. Dis. 12, 569-574.
9. Gocník M, Fislová T, Sládková T, Mucha V, Kostolanský F, Varečková E (2007): Antibodies specific to the HA2 glycopolypeptide of influenza A virus hemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J. Gen. Virol. 88, 951-955.
10. Hashem AM, Van Domselaar G, Li C, Wang J, She YM, Cyr TD, Sui J, He R, Marasco WA, Li X. (2010): Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem. Biophys. Res. Commun. 403, 247-251.
11. Hay A (2000): Functional properties of the virus ion channels. In: Nicholson KG, Webster RG, Hay A (Eds): A Textbook of Influenza. Blackwell Science Ltd, UK, pp. 74-81.
12. Hensley SE, Yewdell JW (2009): Que sera, sera: evolution of the swine H1N1 influenza A virus. Expert Rev. Anti Infect. Ther. 7, 763-768.
13. Horváth A, Tóth GK, Gogolák P, Nagy Z, Kurucz I, Pecht I, Rajnavölgyi E (1998): A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol. Lett. 60, 127-136.
14. Imai M, Sugimoto K, Okazaki K, Kida H (1998): Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res. 53, 129-139.
15. Katz JM, Garg S, Sambhara S (2006): Influenza vaccines: current and future strategies. In Kawaoka Y (Ed.): Influenza Virology: Current Topics. Caister Academic Press, Norfolk, England, pp. 203-228.
16. Lim APC, Chan CEZ, Wong SKK, Chan AHY, Ooi EE, Hnason BJ (2008): Neutralizing human monoclonal antibody against H5N1 influenza HA selected from A Fab-phage display library. Virology J. 5, 1-10.
17. Liu W, Peng Z, Liu Z, Lu Y, Ding J, Chen YH (2004): High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 23, 366-371.
18. Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, Nakajima K (1991): Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 182, 475-485.
19. Okuno Y, Isegawa Y, Sasao F, Ueda S (1993): A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67, 2552-2558.
20. Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, Goutama M, Kwang J (2009): Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 83, 2553-2562.
21. Skehel JJ, Wiley DC (2000): Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569.
22. Stropkovská A, Mucha V, Fislová T, Gocník M, Kostolanský F, Varečková E (2009): Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of Influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin. Acta Virol. 53, 15-20.
23. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen L, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco A (2009): Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature. Structural &Molecular Biology, 1-9.
24. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, Muelen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J (2008): Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3, e3942.
25. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL (2007): Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 13, 426-435.
26. Vanlandschoot P, Beirnaert ER, Barrere B, Calder L, Millar B, Wharton S, Min Jou W, Fiers W (1998): An antibody which binds to the membrane-proximal end of influenza virus hemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus. J. Gen. Virol. 79, 1781-1791.
27. Varečková E, Mucha V, Wharton SA, Kostolanský F (2003a): Inhibition of fusion activity of influenza A hemagglutinin mediated by HA2-specific monoclonal antibodies. Arch. Virol. 148, 469-486.
28. Varečková E, Wharton SA, Mucha V, Gocník M, Kostolanský F (2003b): A monoclonal antibody specific to the HA2 glycoprotein of influenza A virus hemagglutinin that inhibits its fusion activity reduces replication of the virus. Acta Virol. 47, 229-236.
29. Webster RG (2006): H5 influenza viruses. In Kawaoka Y (Eds): Influenza Virology: Current Topics. Caister Academic Press, Norfolk, England, pp. 281-298.